Simple, readily available clinical indices predict early and late mortality among patients with ANCA-associated vasculitis

BMC Nephrology

Research Article

István Mucsi¹  László Rosivall²  Gábor Kökény²  Kálmán Polner³  Henrik Braunitzer³  József Arányi³  Ágnes Haris³  Ilona Kaszás⁴ 

[1] Department of Medicine (Nephrology), University of Toronto, Kidney Transplant Program, Toronto General Hospital, University Health Network, 585 University Avenue, M5G 2 N2, Toronto, ON, Canada;Institute of Pathophysiology, Semmelweis University, 4 Nagyvárad tér, 1089, Budapest, Hungary;Nephrology Department, Szent Margit Hospital, 132 Bécsi út, 1032, Budapest, Hungary;Pathology Department, Szent Margit Hospital, 132 Bécsi út, 1032, Budapest, Hungary;

关键词: ANCA;    BVAS;    Comorbidity;    Immunosuppression;    Outcome;    Vasculitis;   

DOI  :  10.1186/s12882-017-0491-z

 received in 2015-12-02, accepted in 2017-02-15,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe early identification of patients with ANCA-associated vasculitis (AAV) who are at increased risk for inferior clinical outcome at the time of diagnosis might help to optimize the immunosuppressive therapy. In this study we wanted to determine the predictive value of simple clinical characteristics, which may be applicable for early risk-stratification of patients with AAV.MethodsWe retrospectively analyzed the outcome of 101 consecutive patients with AAV receiving a protocolized immunosuppressive therapy. Baseline Birmingham Vasculitis Activity Score (BVAS) and non-vasculitic comorbidities were computed, then predictors of early (<90 days) and late (>90 days) mortality, infectious death, relapse and end stage kidney disease (ESKD) were evaluated.ResultsThe baseline comorbidity score independently predicted early mortality (HR 1.622, CI 1.006–2.614), and showed association with infectious mortality (HR 2.056, CI 1.247–3.392). Patients with BVAS at or above median (=21) had worse early mortality in univariable analysis (HR 3.57, CI 1.039–12.243) (p = 0.031), and had more frequent relapses (p = 0.01) compared to patients with BVAS below median.ConclusionsAssessing baseline comorbidities, beside clinical indices characterizing the severity and extension of AAV, might help clinicians in risk-stratification of patients. Future prospective studies are needed to investigate whether therapies based on risk-stratification could improve both short term and long term survival.

【 授权许可】

CC BY   
© The Author(s). 2017